Top Markets
Coin of the day
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Ранг среди акций #18404
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Цена акции
$5.81
Последняя синхронизация: 2023-02-28
Рыночная капитализация
$200.14M
Изменение (1 день)
-0.34%
Изменение (1 год)
0.00%
Страна
US
Торговля KemPharm, Inc. (KMPH)

Категория

EPS для KemPharm, Inc. (KMPH)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций KemPharm, Inc., текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании KemPharm, Inc. с 2026 по 2026
EPS на конец каждого года
Год EPS Изменить
Недостаточно данных для указанных дат.
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH